Skip to Content

CytoDyn Inc CYDY

Morningstar Rating
$0.16 +0.01 (6.16%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CYDY is trading at a 56% discount.
Price
$0.15
Fair Value
$8.23
Uncertainty
Extreme
1-Star Price
$5.38
5-Star Price
$2.53
Economic Moat
Qvw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYDY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.15
Day Range
$0.150.16
52-Week Range
$0.130.42
Bid/Ask
$0.15 / $0.16
Market Cap
$153.97 Mil
Volume/Avg
662,955 / 2.5 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
12

Comparables

Valuation

Metric
CYDY
VIR
CHRS
Price/Earnings (Normalized)
Price/Book Value
0.71
Price/Sales
28.390.79
Price/Cash Flow
Price/Earnings
CYDY
VIR
CHRS

Financial Strength

Metric
CYDY
VIR
CHRS
Quick Ratio
0.018.681.14
Current Ratio
0.089.051.43
Interest Coverage
−7.55−4.88
Quick Ratio
CYDY
VIR
CHRS

Profitability

Metric
CYDY
VIR
CHRS
Return on Assets (Normalized)
−363.12%−20.03%−27.74%
Return on Equity (Normalized)
−25.63%
Return on Invested Capital (Normalized)
−28.31%−32.60%
Return on Assets
CYDY
VIR
CHRS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJyfzvgdlfNhym$550.4 Bil
VRTX
Vertex Pharmaceuticals IncJtvvqhbhnWhzrgm$101.7 Bil
REGN
Regeneron Pharmaceuticals IncHnkdmgbccGyfbw$98.1 Bil
MRNA
Moderna IncQsthlvftPwpk$39.1 Bil
ARGX
argenx SE ADRMpvgfzzjPwhry$21.7 Bil
BNTX
BioNTech SE ADRVcqjcgpfYpnn$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncSfdbmzbjxQsrtd$18.4 Bil
BMRN
Biomarin Pharmaceutical IncRsjkvwrgwJxqcmv$17.1 Bil
RPRX
Royalty Pharma PLC Class ALdzbpspkZwflf$12.5 Bil
INCY
Incyte CorpDxmphpznzLwqvgdh$11.9 Bil

Sponsor Center